ViiV / Gilead

ViiV Publikationen vom CROI Kongress 2025

*denotes ViiV-supported investigator led and collaborative studies

DOLUTEGRAVIR-based regimens
Risk of Incident Hypertension with Common Antiretroviral Agent Combinations in the OPERA Cohort Philip C. Lackey et al. - Poster	View Poster
Immunological impact of short-term BCL-2 inhibition at ART initiation on SIV infected rhesus macaques* Tomas Raul Wiche Salinas et al. - Oral Presentation	View Abstract
Drug interactions between dolutegravir (DOLUTEGRAVIR-based regimens) and escalating doses of rifampicin (RIF): DORIS study* Yashna Singh et al. - Poster	View Abstract
Depression, Sleep, and Anxiety among pregnant and postpartum women using Dolutegravir and Efavirenz* Danni Wu et al. - Poster	View Abstract
Dolutegravir-based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV-negative controls* Rebecca Ryan et al. - Oral Presentation	View Abstract
PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023)* Jeremiah D. Momper et al. - Poster	View Abstract
Baseline and emergent resistance profiles in the African paediatric CHAPAS-4 trial* Alasdair Bamford et al. - Poster	View Abstract
Risk of obesity, cardiometabolic disease and MACE after switch to an integrase inhibitor in REPRIEVE* Emma M. Kileel et al. - Poster	View Abstract
Impact of art simplification with dolutegravir and lamivudine on the HIV reservoir* Céline Fombellida-Lopez et al. - Poster	View Abstract
Switch to DOLUTEGRAVIR-based regimens/3TC vs BIC/FTC/TAF (PASO-DOBLE study): Efficacy and Weight Changes by Predefined Subgroups* Juan M. Tiraboschi et al. - Poster	View Abstract
Switching to DOLUTEGRAVIR-based regimens/3TC vs. BIC/FTC/TAF and Steatotic Liver Disease: A Sub-study of PASODOBLE Trial* Juan Pineda et al. - Poster	View Abstract
Effectiveness and inflammatory markers after 144 weeks of switch to DOLUTEGRAVIR-based regimens/3TC in a randomized trial* Evy Blomme et al. - Poster	View Abstract
Rapid clearance of the inducible HIV-1 reservoir after initiation of antiretroviral therapy* Maria C. Puertas et al. - Poster	View Abstract
Changes in body composition in people with HIV switching to DOLUTEGRAVIR-based regimens/3TC or BIC/TAF/FTC* S. Di Gregorio et al. - Poster	View Abstract
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment
Long-term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort Michael Sension et al. - Poster	View Poster
Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort Jessica Altamirano et al. - Poster	View Poster
Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort Paul Sax et al. - Poster	View Poster
Decreasing oral induction duration in support of LAI ART use with hardly-reached populations* Aadia I Rana et al. - Poster	View Abstract
At Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in Adherence Challenged PWH* Megan Dieterich et al. - Poster	View Abstract
Safety and Pharmacokinetics of long-acting Cabotegravir and Rilpivirine in children between 20-40kgs* Moherndran Archary et al. - Oral Presentation	View Abstract
CABOTEGRAVIR Long-acting for prevention
PILLAR Month 12 clinical results: Zero HIV acquisition and high persistence with CAB LA for PrEP Taimur Khan et al. - Oral Presentation	View Poster
No increased risk for hypertension with CAB-LA compared to TDF/FTC for PrEP: results from HPTN 084* Sinead Delany-Moretlwe et al. - Poster	View Abstract
Performance of HIV RNA screening in the context of long-acting injectable cabotegravir in HPTN 084* Delany-Moretlwe et al. - Oral Presentation	View Abstract
High incidence of curable sexually transmitted infections in HPTN 084: a tertiary analysis* Harriet Nuwagaba-Biribonwoha et al. - Poster	View Abstract
PrEP Choices Among Sexual and Gender Minorities in Brazil: the ImPrEP CAB-LA Study* Beatriz Grinsztejn et al. - Poster	View Abstract
Depression and Suicide Risk Among Sexual and Gender Minorities: Insights from the ImPrEP CAB Brasil* David Richer et al. - Poster	View Abstract
Patterns of First Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents from Sexual and Gender Minorities in Brazil* Laio Magno et al. - Poster	View Abstract
Acceptability of long-acting cabotegravir among pregnant and lactating people in South Africa* Nafisa Wara et al. - Poster	View Abstract
Impact of rapid long-acting prep scale-up among MSM: closing the unmet needs and towards ending HIV* Haoyi Wang et al. - Poster	View Abstract
Response to HIV Treatment After Long-Acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083* Raphael J. Landovitz et al. - Oral Presentation	View Abstract
Expanding the PrEP method market: Early insights from offering oral PrEP, PrEP ring, and injectable CABOTEGRAVIR Long-acting for prevention for HIV prevention across five countries in Africa* Nicolette Naidoo et al. - Poster	View Abstract
Dynamic Choice HIV Prevention in the context of Injectable Cabotegravir (CAB-LA): a model-based cost-effectiveness analysis* Andrew Phillips et al. - Poster	View Abstract
ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations* Beatriz Grinsztejn et al. - Oral Presentation	View Abstract
Estimation of prevention-effective CAB-LA concentrations among MSM/TGW in HPTN 083* Hanscom B et al. - Oral Presentation	View Abstract
Use of DNA profiling to resolve discrepant HIV tests in the setting of injectable cabotegravir PrEP* Jessica M. Fogel et al. - Poster	View Abstract
Fostemsavir
Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in The Trio Cohort Moti Ramgopal et al. - Poster	View Poster
Pipeline
Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor Luise Rogg et al. - Oral Presentation	View Poster
Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor Rulan Griesel et al. - Oral Presentation	View Poster
VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study Babafemi Taiwo et al. - Oral Presentation	View Poster
Pre-clinical evaluation of effector function-enhanced variants of N6 bnAb David Wensel et al. - Poster	View Poster
Other HIV-related data
Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs) Robert Ferris et al. - Poster	View Poster
Cancer incidence in women with HIV in Europe and Australia: a combined D:A:D and RESPOND cohort analysis Win Min Han et al. - Poster	View Poster
Determinants of steatotic liver disease among people with HIV in Europe and Australia Carlotta Riebensahm et al. - Poster	View Poster
Hospitalization Incidence Among Young Children Living with HIV in the Western Cape, South Africa Kim Anderson et al. - Poster	View Poster
People with HIV at high cardiovascular risk were undertreated with statins* Stefan Esser et al. - Poster	View Abstract
Increasing Methamphetamine Use and Group Sex Observed in MSM with Acute HIV Infection in Bangkok* Phillip Chan et al. - Poster	View Abstract
Statin Effect Heterogeneity on Plaque Volume & Composition in the REPRIEVE Mechanistic Substudy* Zhou Xiner et al. - Poster	View Abstract
Frailty is Associated with Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects* Kristine M. Erlandson et al. - Oral Presentation	View Abstract
No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People with HIV* Kristine M. Erlandson et al. - Poster	View Abstract
Plaque, Inflammation, Subclinical Myocardial Injury and MACE in the REPRIEVE Mechanistic Substudy* Lu MT et al. - Oral Presentation	View Abstract
Prognostic Factors of Physical Function Decline in the PREPARE Study* Grace L. Ditzenberger et al. - Poster	View Abstract
Time-updated win ratio aligns with primary REPRIEVE findings and suggests early pitavastatin benefit* Emma Davies Smith et al. - Poster	View Abstract
Heart Failure Risk and Events in People With HIV in the REPRIEVE Trial* Maya Watanabe et al. - Poster	View Abstract
Cognitive Trajectories 1 year before and after COVID-19 in an AHI cohort* Ferron Ocampo et al. - Poster	View Abstract
ART Exposure and Accelerated Aging in PLHIV: Insights from Proteomic and Methylation Clocks* Nadira Vadaq et al. - Poster	View Abstract
Modulation of CCR5 Expression is Critical for the Maintenance of HIV Control and Reservoir Size* Jéssica C. dos Santos et al. - Poster	View Abstract
Genetic regulation of immune responses to CMV in spontaneous HIV controllers* Suzanne D.E. Ruijten et al. - Poster	View Abstract
Delayed HIV-1 rebound correlates with enhanced CD8 T Cell activation in human trials* Ashan Dayananda et al. - Poster	View Abstract
Virulent HIV-1B: Clinical Challenges and Proteomic Insights* Kavita Mehta et al. - Poster	View Abstract
Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV* Louise E. van Eekeren et al. - Poster	View Abstract
Brain volume normalization after 96 weeks of ART started during acute HIV infection* Robert Paul et al. - Oral Presentation	View Abstract
People with HIV exhibit structural brain changes following infection with SARS-COV-2* Jacob Bolzenius et al. - Oral Presentation	View Abstract
Mitochondrial Gene Variants in VARS2 Influence HIV Reservoir and T Cells in European HIV Controllers* Victoria Rios-Vazquez et al. - Poster	View Abstract
Multi-omics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort* Victoria Rios-Vazquez et al. - Poster	View Abstract
Heterogeneity of PD-1 expression in People Living with HIV and its relationship with host and viral-related factors* Adriana Navas et al. - Poster	View Abstract
Residual HIV viremia: association with reservoir, functional immunology and systemic inflammation* Twan Otten et al. - Poster	View Abstract
Neuronal Injury in a Subset of Individuals during Acute HIV Infection and After Immediate Treatment* Phillip Chan et al. - Poster	View Abstract
Early HIV-1 genetic diversity includes CTL and drug resistance mutations* Adam A. Capoferri et al. - Poster	View Abstract
RV550: The effects of IL-15 super-agonist N-803 with ART in acute infection on T and NK cells* Hiroshi Takata et al. - Poster	View Abstract
RV550: Safety and virological outcomes in blood and lymph nodes of N-803 with ART in acute infection* Carlo Sacdalan et al. - Poster	View Abstract
Sex-based differences and genetic regulation of cytokine responses in people living with HIV* Suzanne D.E. Ruijten et al. - Poster	View Abstract
Females With HIV Favor Interferon Responses Over Inflammation Upon TLR7 Activation* Alisa Huber et al. - Poster	View Abstract
Maximizing Benefits to Participants in Analytic Treatment Interruption Studies with bnAb infusions* Yifan Li et al. - Poster	View Abstract
Neutralization sensitivity of viral reservoir envelopes to broadly neutralizing antibodies VRC07-523LS and PGDM1400LS* Gabriel Smith et al. - Poster	View Abstract

Gilead-initiated or Gilead-supported Abstracts Published at CROI 2025

	F/TAF
Glidden, D	WEIGHT CHANGE ON F/TAF VS PLACEBO: USING COMMON F/TDF GROUPS TO BRIDGE DATA ACROSS CLINICAL TRIALS
Mujuru, HA	WEEK 24 OUTCOMES OF F/TAF PLUS COBICISTAT-BOOSTED PROTEASE INHIBITORS IN CHILDREN ≥2 Y AND ≥14 KG
	B/F/TAF
Avihingsanon, A	ALLIANCE OLE: SWITCH TO B/F/TAF IN PEOPLE WITH BOTH HIV-1 AND HBV
D’Antoni, M	HIV-1 RESISTANCE ANALYSIS OF TREATMENT-NAÏVE PEOPLE WITH HIV AND HBV RECEIVING B/F/TAF OR DTG+F/TDF
Post, F	RENAL OUTCOMES IN PEOPLE WITH HIV-1 AND RENAL IMPAIRMENT TREATED WITH B/F/TAF IN RANDOMIZED TRIALS
	TREATMENT PIPELINE
Ogbuagu, O	EFFICACY AND SAFETY OF LONG-ACTING LENACAPAVIR, TEROPAVIMAB, AND ZINLIRVIMAB: PHASE 2 PRIMARY OUTCOME WEEK 26
Imperial, M	PHARMACOKINETIC MODELING OF MISSED DOSE SCENARIO OF ORAL WEEKLY ISLATRAVIR PLUS LENACAPAVIR
Hansen, D	IN VITRO RESISTANCE PROFILE FOR GS-1720, A POTENT ONCE-WEEKLY ORAL INSTI IN CLINICAL DEVELOPMENT
VanderVeen, L	RESISTANCE ANALYSIS OF WEEKLY ISLATRAVIR PLUS LENACAPAVIR IN PEOPLE WITH HIV AT 48 WEEKS
Margot, N	BICTEGRAVIR + LENACAPAVIR: BASELINE AND WEEK 48 RESISTANCE IN ARTISTRY-1 PHASE 2
	HIV PREVENTION INCLUDING PIPELINE
Gill, K	LENACAPAVIR PHARMACOKINETICS, SAFETY, AND EFFICACY IN ADOLESCENTS AND ADULTS IN PURPOSE 1
Jogiraju, V	PHARMACOKINETICS AND SAFETY OF ONCE-YEARLY FORMULATIONS OF LENACAPAVIR
Kiweewa, FM	ADHERENCE TO F/TAF IN CISGENDER WOMEN PREVENTS HIV WITH LOW RISK OF RESISTANCE OR DIAGNOSTIC DELAY
Tao, L	THE INFLUENCE OF RACIALIZED ECONOMIC SEGREGATION ON UNMET HIV PREVENTION NEEDS IN THE REAL WORLD
Mansoor, LE	PURPOSE 1: PREFERENCE FOR TWICEYEARLY INJECTION VS DAILY ORAL PILLS FOR HIV PREP IN CISGENDER WOMEN
Montgomery, ET	QUALITATIVE ASSESSMENT OF ACCEPTABILITY AND PREFERENCES FOR INJECTABLE AND ORAL PREP IN PURPOSE 1
Tao, L	US SOCIOECONOMIC DISPARITIES AND GEOGRAPHIC VARIATIONS IN HIV PREEXPOSURE PROPHYLAXIS PROVIDERS
	HIV CURE
Dong, K	EVALUATION OF 2 BNABS PLUS VESATOLIMOD IN EARLY-TREATED SOUTH AFRICAN WOMEN WITH HIV-1 DURING ATI
Huang, S	T-CELL RESPONSES INDUCED BY GS-1966+GS-1144 VACCINES IN VIRALLY SUPPRESSED PEOPLE WITH HIV
	HIV TREATMENT (OTHER)
Mignano, J	DETECTION AND LINKAGE OF PLWH WHO ARE OUT OF CARE IN 94 EMERGENCY DEPARTMENTS ACROSS THE US
	COVID-19
Berry, M	PATTERNS OF REMDESIVIR INITIATION IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED WITH COVID-19
Ferreira, AM	MACHINE LEARNING IDENTIFIES PREDICTORS OF DELAYED OR NO REMDESIVIR USE IN HOSPITALIZED COVID-19 PATIENTS

Locally Supported Studies, Investigator-Sponsored Research and Collaborative Studies: CROI 2025

	B/F/TAF
Osuala, E	PHARMACOKINETICS OF TWICE-DAILY TAF IN ADULTS WITH HIV-ASSOCIATED TB ON BIC/FTC/TAF AND RIFAMPICIN
Loutfy, M	ESTRADIOL CONCENTRATIONS IN TRANS WOMEN ON B/F/TAF COMPARED TO THOSE WITHOUT HIV
Coppinger, C	PHARMACOKINETICS OF SWITCHING TO B/F/TAF IN PWH POST RENAL TRANSPLANT: BIC-SWITCH STUDY
Behrens, G	INTEGRASE INHIBITOR VERSUS PROTEASE INHIBITOR-BASED THERAPY FOR PATIENTS WITH ADVANCED HIV-DISEASE
Ombajo, L	SWITCH OF VIRALLY SUPPRESSED ADULTS ? 60 YEARS FROM FIRST-LINE ART TO B/F/TAF: WEEK 96 RESULTS
Diaz-Garcia, C	INFLAMMATORY SIGNATURES AMONG PEOPLE WITH HIV INITIATING DTG/3TC VS. B/F/TAF IN THE CORIS COHORT
Serrano-Villar, S	IMPACT OF SWITCHING FROM DTG/3TC TO B/F/TAF ON WEIGHT, CHOLESTEROL, AND INFLAMMATION IN HIV
	B/F/TAF
Ryan, P	SIMPLIFIED ACCESS AND RETENTION MODEL FOR VULNERABLE PEOPLE WITH HIV: SIMPLIFIED STUDY RESULTS
Peyrouny-Mazeau, A	PREDICTIVE FACTORS OF VIROLOGICAL FAILURE AFTER SWITCHING TO B/F/TAF (ANRS-CO3-AQUIHIV-NA)
Marc, J	HIGH PREVALENCE OF BASELINE NRTI RESISTANCE IN PWH SWITCHED FROM SECOND-LINE PI/R TO B/F/TAF
Bellecave, P	REAL-WORLD ROBUSTNESS OF B/F/TAF AT VIROLOGIC FAILURE IN THE ANRS-CO3- AQUIHIV-NA COHORT
Bourgi, K	RE-EXAMINING INSTI EFFECTS ON WEIGHT GAIN AMONG TREATMENT-NAÏVE PEOPLE WITH HIV IN NORTH AMERICA
Homeus, F	WEIGHT CHANGE IN TRIAL OF SWITCHING FROM SECOND-LINE bPI TO B/F/TAF IN A CONTEXT OF FOOD INSECURITY
	F/TAF
Bamford, A	GENOTYPIC RESISTANCE IN THE AFRICAN PAEDIATRIC CHAPAS-4 TRIAL OF SECOND-LINE ANTIRETROVIRAL THERAPY
	LENACAPVIR HIV TREATMENT
Mounzer, K	FIRST YEAR OF LENACAPAVIR LONG-ACTING INJECTABLE USE IN THE OPERA COHORT
	PREGNANCY
Wu, D	DEPRESSION, SLEEP, AND ANXIETY AMONG PREGNANT AND POSTPARTUM WOMEN USING DOLUTEGRAVIR AND EFAVIRENZ
	Acute HIV Infection
Paul, R	BRAIN VOLUME NORMALIZATION AFTER 96 WEEKS OF ART STARTED DURING ACUTE HIV INFECITON
Capoferri, A	EARLY HIV-1 GENETIC DIVERSITY INCLUDES CTL AND DRUG RESISTANCE MUTATIONS
Takata, H	RV550: IL-15 SUPERAGONIST N-803 WITH ART IN ACUTE HIV INFECTION ENHANCES T AND NK CELL PROLIFERATION
Sacdalan, C	RV550: SAFETY AND VIROLOGICAL OUTCOMES IN BLOOD AND LYMPH NODES OF N-803 WITH ART IN ACUTE INFECTION
Chan, P	NEURONAL INJURY IN A SUBSET OF PWH DURING ACUTE HIV INFECTION AND UP TO 5 YEARS AFTER IMMEDIATE ART
Chan, P	INCREASING METHAMPHETAMINE USE AND GROUP SEX OBSERVED IN MSM WITH ACUTE HIV INFECTION IN BANGKOK
	CVD & WEIGHT
Lu, M	PLAQUE, INFLAMMATION, SUBCLINICAL MYOCARDIAL INJURY AND MACE IN THE REPRIEVE MECHANISTIC SUBSTUDY
Erlandson, K	NO EVIDENCE OF A DETRIMENTAL EFFECT OF PITAVASTATIN ON NEUROCOGNITIVE FUNCTION AMONG PEOPLE WITH HIV
Bloomfield, G	HEART FAILURE RISK AND EVENTS IN PEOPLE WITH HIV IN THE REPRIEVE TRIAL
Kileel, E	RISK OF OBESITY, CARDIOMETABOLIC DISEASE AND MACE AFTER SWITCH TO AN INTEGRASE INHIBITOR IN REPRIEVE
Zhou, X	STATIN EFFECT HETEROGENEITY ON PLAQUE VOLUME & COMPOSITION IN THE REPRIEVE MECHANISTIC SUBSTUDY
Smith, E	TIME-UPDATED WIN RATIO ALIGNS WITH PRIMARY REPRIEVE FINDINGS AND SUGGESTS EARLY PITAVASTATIN BENEFIT
Mavarani, L	RISK FACTORS ASSOCIATED WITH EXTREME WEIGHT GAIN IN PEOPLE WITH HIV
	Liver Health
Liegeon, G	IMPACT OF A HCV TEST AND TREAT CAMPAIGN ON HEPATITIS C INCIDENCE IN THE ANRS PREVENIR PREP STUDY
Riebensahm, C	DETERMINANTS OF STEATOTIC LIVER DISEASE AMONG PEOPLE WITH HIV IN EUROPE AND AUSTRALIA
	Cancer
Han, W	CANCER INCIDENCE IN WOMEN WITH HIV: A COMBINED D:A:D AND RESPOND ANALYSIS
	COVID-19
Bolzenius, J	STRUCTURAL BRAIN VOLUMES DECREASE AFTER SARS-COV-2 INFECTION AMONG PEOPLE WITH HIV
Huang, L	LONG COVID IS A MULTISYSTEM DISORDER: ASSESSMENT OF THE NATIONAL ACADEMIES DEFINITION
Ocampo, F	COGNITIVE TRAJECTORIES 1 YEAR BEFORE AND AFTER COVID-19 IN AN EARLY TREATED HIV COHORT
Ocampo, F	IMMUNE & VIROLOGIC TRAJECTORIES 1.5 YEARS BEFORE AND AFTER COVID-19 IN AN EARLY-TREATED HIV COHORT
	Frailty
Erlandson, K	FRAILTY IS ASSOCIATED WITH HIGHER MACE INCIDENCE BUT DOES NOT APPEAR TO MODIFY PITAVASTATIN EFFECTS
Kulik, G	PROGNOSTIC FACTORS OF PHYSICAL FUNCTION DECLINE IN THE PREPARE STUDY
	HIV TREATMENT (OTHER)
Vo, P	UNTANGLING THE IMPACT OF CD101 ON HIV-1 TRANSMISSION
Magagnoli, J	IMPACT OF RESISTANCE TO ANTIRETROVIRAL THERAPY AMONG VETERANS WITH HUMAN IMMUNODEFICIENCY VIRUS
Garcia-Deltoro, M	DEVELOPMENT OF A HIV RISK PREDICTION MODEL USING ELECTRONIC HEALTH RECORD DATA IN SPAIN
	HIV CURE
Smith, G	SENSITIVITY OF HIV-1 CRF01_AE ENVELOPES TO BROADLY NEUTRALIZING ANTIBODIES VRC07-523LS AND PGDM1400LS
Takata, H	TARGETING TCF-1 TO POTENTIATE THE FUNCTIONAL CAPACITY OF HIV/SIV-SPECIFIC CD8+ T CELLS
Li, Y	MAXIMIZING BENEFITS TO PARTICIPANTS IN ANALYTIC TREATMENT INTERRUPTION WITH ANTIBODY INFUSIONS
	HIV PREVENTION
Hanscom, B	ESTIMATION OF PREVENTION-EFFECTIVE CAB-LA CONCENTRATIONS AMONG MSM/TGW IN HPTN 083
Delany- Moretlwe, S	PERFORMANCE OF HIV RNA SCREENING IN THE CONTEXT OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN HPTN 084
Landovitz, R	RESPONSE TO HIV TREATMENT AFTER LONG-ACTING CABOTEGRAVIR PREEXPOSURE PROPHYLAXIS IN HPTN 083
Delany- Moretlwe, S	NO INCREASED RISK FOR HYPERTENSION WITH CAB-LA COMPARED TO TDF/FTC FOR PREP: RESULTS FROM HPTN 084
Bunting, S	HIV DIAGNOSIS FOLLOWING DISCHARGE FROM PSYCHIATRIC HOSPITALIZATION: A CLAIMS-BASED, REAL-WORLD STUDY
Fogel, J	USE OF DNA PROFILING TO RESOLVE DISCREPANT HIV TESTS IN THE SETTING OF INJECTABLE CABOTEGRAVIR PREP
Yin, Z	LEVERAGING COMMUNITY TO PROVIDE PREP TO KEY POPULATION IN CHINA: RESULTS FROM A PREP CLINICAL TRIAL
	HIV PREVENTION
Nuwagaba- Biribonwoha, H	HIGH INCIDENCE OF CURABLE SEXUALLY TRANSMITTED INFECTIONS IN HPTN 084: A TERTIARY ANALYSIS
Kabami, J	HIGH STI PREVALENCE AND LOW PAST PREP USE AMONG WOMEN WHO ENGAGE IN SEX WORK IN SOUTHWESTERN UGANDA
Li, C	DIGITAL STRATEGY TO IMPROVE PREP ADHERENCE AMONG MSM: A STEPPED-WEDGE RANDOMIZED TRIAL IN CHINA